David Hart Appointed New CEO of the Bermuda Business Development Agency (BDA)
7.9.2021 18:57:00 EEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA) announced today that Mr. David Hart has been appointed as the new Chief Executive Officer (CEO) of the BDA effective 1 October 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005694/en/
David Hart, new BDA CEO (Photo: Business Wire)
Prior to joining the BDA, Mr. Hart served as Executive Vice President of the Florida Chamber of Commerce, one of the largest and most successful business advocacy organisations in the United States, where he was part of the leadership team responsible for consistently enhancing the environment to increase job growth, diversify the economy and attract additional capital investments. Through collaborations with public and private sector partners these efforts contributed to Florida creating one of every 11 jobs in the United States, attracting $1.19 million in capital every hour, and recently becoming ranked as the 15th largest economy in the world.
Mr. Hart said, “I am very excited and honoured to be joining the BDA team. The BDA’s mission of fostering sustainable, equitable prosperity for Bermuda, and encouraging jobs, investment, and innovation to come to the Island, has never been more important. I am thrilled to join a world class team and accelerate our efforts to bring investment and jobs to Bermuda. Bermuda’s track record of leadership on a global scale, access to world markets and talented pool of human capital are significant strengths as we seek to diversify Bermuda’s economy and support our trading partners worldwide.”
Stephen Weinstein, BDA Chair said, “On behalf of the Board of Directors, we welcome Mr. Hart to the BDA and the Bermuda community at this critical time. His leadership, communication skills, and deep experience in economic development and public policy, are perfect fits for our next stage of challenges and growth.”
“We thank Roland Andy Burrows for nearly three years of dedicated service as CEO,” Mr. Weinstein said. “Under his leadership, the BDA helped navigate Bermuda through one of its most trying economic periods and we wish him well in his future endeavours.”
Mr. Burrows will continue to support the agency as a senior consultant through year-end to support the leadership transition.
Mr. Burrows said, "The BDA plays a vital role in promoting Bermuda. I am proud of what the BDA has achieved since December 2018 and will continue to support its mission.”
Mr. Hart’s new appointment highlights the Board’s and the BDA’s continued commitment to international business development. With an aim to increase international investment through innovation, strategic partnerships and targeted marketing of Bermuda’s world class business platform, the BDA has also created a new Business Development Committee chaired by BDA board member George Thomas. Mrs. Susan Pateras, BDA Deputy Chair, has been appointed Interim CEO and will oversee operations until Mr. Hart commences service. Mr. Hart’s service in Bermuda is subject to Bermuda Immigration approval.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005694/en/
Contact information
Stuart Roberts, Director of Communications & PR
stuart@bda.bm
+1 441 707 0038
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
